Clinical safety of low-dose anticoagulation with fondaparinux in patients undergoing peripheral endovascular treatment due to critical limb-threatening ischaemia - a pilot study.
Anticoagulants
/ therapeutic use
Endovascular Procedures
Female
Femoral Artery
/ surgery
Fondaparinux
/ therapeutic use
Humans
Ischemia
/ diagnosis
Limb Salvage
Peripheral Arterial Disease
Pilot Projects
Platelet Aggregation Inhibitors
/ therapeutic use
Popliteal Artery
/ surgery
Prospective Studies
Retrospective Studies
Stents
Treatment Outcome
Vascular Patency
Critical limb ischaemia
drug-coated balloon
dual platelet therapy (DAPT)
duplex sonography
fondaparinux
lower limb
stent placement
Journal
Acta cardiologica
ISSN: 1784-973X
Titre abrégé: Acta Cardiol
Pays: England
ID NLM: 0370570
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
pubmed:
14
3
2020
medline:
6
11
2021
entrez:
14
3
2020
Statut:
ppublish
Résumé
To evaluate the safety and effectiveness of fondaparinux in addition to dual antiplatelet therapy (DAPT) in patients with critical limb-threatening ischaemia (CLTI). Fondaparinux (2.5 mg/d) was administered for 1-4 weeks after endovascular procedures together with DAPT ( Twenty-four patients (78.7 ± 6.9 years, 14 [58%] female, 4 TASC B, 10 TASC C and 10 TASC D lesions, total lesion length = 210 ± 98 mm, mean Rutherford class = 4.7 ± 0.6) received fondaparinux (over a period of 22 ± 9 d, range 7-28 d) and DAPT Adding fondaparinux to DAPT does not seem to result in excess of clinically relevant bleeding. Our preliminary data suggest that prospective studies are now warranted in larger patient cohorts. DRKS00015856.
Identifiants
pubmed: 32167029
doi: 10.1080/00015385.2020.1737782
doi:
Substances chimiques
Anticoagulants
0
Platelet Aggregation Inhibitors
0
Fondaparinux
J177FOW5JL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM